A Phase 1b Trial of Hu5F9-G4 in Combination With Avelumab in Solid Tumor Patients and Checkpoint-Inhibitor-Naive Ovarian Cancer Patients Who Progress Within 6 Months of Prior Platinum Chemotherapy

Trial ID # NCT03558139
Phase Ib
Drug Class Immunotherapy: Checkpoint Inhibitors/CD47
Drug Name Magrolimab
Alternate Drug Names anti-CD47 monoclonal antibody Hu5F9-G4, Hu5F9-G4
Drugs in Trial Avelumab, Magrolimab
Eligible Participant

Platinum resistant or refractory ovarian cancer

Patients Enrolled

18

Therapy Setting

Recurrence

Study Design

Open-Label, Non-randomized

Endpoints

DCR, evaluated per RECIST

Efficacy

DCR: 56% (10SD, n=18)

Clinically Significant Adverse Events

Serious AE:
Grade 3-4 AE:

Conclusion

Magrolimab+avelumab is a novel, well-tolerated combination with a 56% stable disease rate in ovarian cancer patients

Reference

Lakhani NJ et al. A phase Ib study of the anti-CD47 antibody magrolimab with the PD-L1 inhibitor avelumab (A) in solid tumor (ST) and ovarian cancer (OC) patients. J Clin Oncol (2020) 38 (suppl 5; abstr 18)
https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.5_suppl.18

Contact Us
Contact Us

We are here to help! Send us a message below or give us a call at (858) 657-0282.